; (B) develop better understanding of the etiology of the disease (including an analysis of lifestyle factors proven to be involved in higher rates of prostate cancer, such as obesity and diet, and in different ethnic, racial, and socioeconomic groups, such as the African-American, Latino or Hispanic, and American Indian populations and men with a family history of prostate cancer) to improve prevention efforts; (C) expand basic research into prostate cancer, including studies of fundamental molecular and cellular mechanisms; (D) identify and provide clinical testing of novel agents for the prevention and treatment of prostate cancer; (E) establish clinical registries for prostate cancer; (F) use the National Institute of Biomedical Imaging and Bioengineering and the National Cancer Institute for assessment of appropriate imaging modalities; and (G) address such other matters relating to prostate cancer research as may be identified by the Federal agencies participating in the program under this subsection. (2) Prostate Cancer Advisory Board There is established in the Office of the Chief Scientist of the Food and Drug Administration a Prostate Cancer Scientific Advisory Board. Such board shall be responsible for accelerating real-time sharing of the latest research data and accelerating movement of new medicines to patients. (3) Underserved minority grant program In carrying out such program, the Secretary shall— (A) award grants to eligible entities to carry out components of the research outlined in paragraph (1); (B) integrate and build upon existing knowledge gained from comparative effectiveness research; and (C) recognize and address— (i) the racial and ethnic disparities in the incidence and mortality rates of prostate cancer and men with a family history of prostate cancer; (ii) any barriers in access to care and participation in clinical trials that are specific to racial, ethnic, and other underserved minorities and men with a family history of prostate cancer